What is the MD-01 (Monitor Breast) study population?

• A. Stage IV metastatic
• B. Ductal carcinoma in situ only
• C. Male breast cancer only
• D. Stage I-III breast cancer, all subtypes

Answer: (D)

This question is about who is enrolled in the Monitor Breast study and what population the trial is designed to observe after initial treatment. The best answer includes stage I–III breast cancer across all subtypes, because the study aims to monitor outcomes, recurrences, and long-term survival in patients with invasive, non-metastatic disease after curative or locoregional therapy. Stage IV metastatic disease has different endpoints and management, so it’s not the focus here. Ductal carcinoma in situ is non-invasive (stage 0) and typically followed differently from invasive cancers, so it wouldn’t be included in a study targeting post-treatment surveillance of invasive disease. Male breast cancer, while important, represents a small, separate subset and is not the broad, all-subtypes non-metastatic population the Monitor Breast study is designed to evaluate.